Lansoprazol Almus

Lansoprazole, the active ingredient in Lansoprazol Almus, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease, peptic ulcer disease, and erosive esophagitis in adult patients.

GNH USA supplies Lansoprazol Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazol Almus, a proton pump inhibitor, acts on the gastric acid secretion pathway to manage several acid‑related conditions. - Gastroesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing by decreasing gastric acidity. - Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotic combinations. - Erosive esophagitis: promotes mucosal recovery and symptom relief.

Lansoprazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools occurring intermittently. - Nausea: feeling of queasiness without vomiting. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased gas production. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent diarrhea with abdominal pain. - Low magnesium levels: muscle cramps, weakness, or irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: abnormal blood test results indicating hepatic stress.

Before using Lansoprazol Almus, consider the following safety measures. - Assess renal function: adjust use if severe kidney impairment is present. - Evaluate hepatic status: monitor liver function in patients with liver disease. - Review concomitant medications: avoid use with drugs that require an acidic environment for absorption. - Long‑term therapy: limit duration to the shortest effective period to reduce fracture risk. - Pregnancy and lactation: discuss potential risks with a healthcare professional before use. - Store at room temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Lansoprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased antiviral absorption, may lead to treatment failure. - Methotrexate (high dose): increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible enhancement of anticoagulant effect, monitor INR. - Digoxin: increased serum levels, watch for signs of toxicity. - Iron supplements: reduced absorption, consider timing separation.